Navigation Links
Drug, Pacemaker Fight Irregular Heartbeat
Date:9/5/2007

Studies suggest new weapons against dangerous atrial fibrillation

WEDNESDAY, Sept. 5 (HealthDay News) -- Cardiac researchers say a new drug may help treat the abnormal heartbeat called atrial fibrillation.

The drug, dronedarone, is not yet approved by the U.S. Food and Drug Administration but has proven effective in two major trials, with fewer side effects than existing medications, according to a report in the Sept. 6 issue of the New England Journal of Medicine.

And in the same issue of the journal, researchers say a special pacemaker can help prevent the development of atrial fibrillation in people with sinus-node disease -- a dysfunction of the cardiac region controlling heartbeat.

The American Heart Association estimates that 2.2 million Americans, many of them elderly, have atrial fibrillation, in which the two upper chambers of the heart lose their regular rhythm.

The condition increases the risk of dangerous clots forming as blood pools in the heart. Atrial fibrillation is treated with drugs that prevent clot formation and also with medications that restore the heart's normal rhythm.

The two trials -- which were funded by Sanofi-Aventis, the maker of dronedarone -- included more than 1,200 participants with atrial fibrillation.

In one European trial, the heartbeat remained normal for an average of 96 days in those getting dronedarone, compared to 41 days in those getting a placebo. In the other trial, conducted in the United States and several other countries, the heartbeat remained normal for an average of 158 days for those getting dronaderone and 59 days in those getting placebo.

Most important, the incidence of dangerous side effects -- such as occur with an approved drug, amiodarone -- was low in the dronedarone trial, said lead researcher Dr. Bramah N. Singh, a professor of medicine at the University of California at Los Angeles. Amiodarone can affect the thyroid, liver and lungs.

"Up to this time, there have been no cases of pulmonary fibrosis [associated with dronedarone], which is the most deadly complication that a patient can have," Singh noted.

Because the incidence of pulmonary fibrosis is low, participants in the trials will continue to be monitored for some time, he said. "But the issue can be resolved relatively quickly," Singh said. "There is a morbidity and mortality trial coming close to being completed, with 4,600 patients. We should have results in six to seven months."

It's also necessary to have a direct comparison of dronedarone vs. amiodarone, he said. "They have not been compared directly in the same population." Singh said. "Until that is actually done, we cannot with confidence say that dronedarone is less effective or more effective."

Direct comparison studies are underway, he said, "and those usually are quickly done, in 12 months or so."

The second atrial fibrillation study, done by a group led by Dr. Michael O. Sweeney, an electrophysiologist at Brigham and Women's Hospital in Boston, included 1,065 participants who had pacemakers installed because of sinus-node disease.

Some 10 percent to 15 percent of Americans over 65 have the condition, Sweeney said, and many have been given pacemakers that stimulate regular beating of the heart's chambers.

The idea behind pacemaking is to speed the abnormally slow heartbeat that occurs with sinus-node disease. However, the conventional pacemaker can boost the risk of atrial fibrillation by increasing the heart rate until the chamber flutters, rather than pumping blood, Sweeney explained.

Some participants in the trial got pacemakers that acted on just the ventricles, the lower chambers of the heart. Atrial fibrillation developed in 7.9 percent of them, compared to 12.7 percent of those with conventional pacemakers.

The study was supported by medical device maker Medtronic.

"This is the first time this technology has been validated in a clinical trial," Sweeney said. "Hopefully it will change the approach to sinus-node disease."

The technique can even be applied to people who already have pacemakers implanted, Sweeney said, since those pacemakers can be reprogrammed. "Patients might want to ask their physicians about the management of ventricular pacing," he said.

More information

There's more on atrial fibrillation at the American Heart Association.



SOURCES: Bramah N. Singh, M.D., professor, medicine, University of California at Los Angeles; Michael O. Sweeney, M.D., electrophysiologist, Brigham and Women's Hospital, Boston; Sept. 6, 2007, New England Journal of Medicine


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. FDA Approves New HIV Drug, Viread
2. FDA Approves New Arthritis Drug, Bextra
3. New Drug, Pleconaril speeds recovery from common cold
4. Multiple Sclerosis drug, Tysabri banned due to neurological disorders
5. Herceptin Not A ‘Wonder’ Drug, Says The Lanct
6. NGO Files Pre-Grant Opposition Against Anti-HIV Drug, Combivir
7. Life-Saving Cancer Drug, Herceptin Will be Available Free for Breast Cancer Patients in Wales
8. Diabetes Drug, Exenatide, Good For Blood Sugar Levels and Weight Loss
9. FDA Gives Approval for Skin Cancer Drug, Zolinza
10. Was the Warning of a Severe Reaction To a Drug, Overlooked?
11. Anti-Craving Drug, Naltrexone Helps Women Quit Smoking
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, affiliated ... Weintraub as a prominent plastic surgeon and the network’s newest partner. , ... most handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone ... executive with extensive sequencing and genomics experience, as Vice President of North American Capital ... will be responsible for leading the sales team in the commercialization of the HTG ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: